Mean and standard deviation of 5-point experience sampling scales for each group (treatment and control) and session (pre and post). by Julio Rodriguez-Larios (18778803)

Comparison of soleus muscle weight and fiber size histogram between young and aged WT and NMIIC KO mice. by Hiroki Hamaguchi (22783780)

Detection of epistasis is rescued by simultaneous analysis of multiple independently-evolved populations. by Gabriele Pedruzzi (5753792)

Decrease of bnAb activity during cell-cell transmission is variable and strain-dependent. by Lucia Reh (546554)

Heat inactivation curves for the WT SULT1A1 protein and the 5C2, 5F8 and D249G SULT1A1 mutants. by Ilana Berger (198531)

“…The decrease in stability of the 5F8 mutant, relative to 1E8, and the D249G mutant, relative to the WT protein, highlight the trade-off between thermostability and the acquisition of new catalytic properties (see text for details).…”

Maf1 is a rapamycin-sensitive regulator of RNAP III-mediated tRNA transcription in <i>S</i>. <i>pombe</i>. by Aneeshkumar G. Arimbasseri (840654)

SMC-specific knockout of Klf5 (smcKlf5^−/−) exacerbates the progression of Ang II–induced AAA by facilitating ROS formation. by Dong Ma (584680)

Percentage decrease in the response time (mean ± std) in the post-training test phase when compared to that in the pre-training phase. by Lilian Fautrelle (711885)

L-cysteine improves blood fluidity impaired by acetaldehyde: <i>In vitro</i> evaluation by Ippo Otoyama (6069815)

“…The blood passage time, percentage of microchannel obstruction, and numbers of adherent WBCs on the microchannel terrace increased after adding ACD in a concentration-dependent manner, whereas they decreased after adding ACD and L-cysteine in a L-cysteine concentration-dependent manner. …”

P-V Fit Scores Across Demographic Factors Among 636 residents. by Yaotian Fan (5917766)

Subjects:

The relative change in incident cases of RA among AYAs between 1990 and 2019. by Ruibo Li (2063167)

Global map of 2019 incidence of RA among AYAs. by Ruibo Li (2063167)

Fig 4 - by Ruibo Li (2063167)

Fig 3 - by Ruibo Li (2063167)

Avertin®-induced decrease in basal particle transport speed (PTS) remains unaffected in WT mice in the presence of TASK-1 inhibitors and in TASK-1 KO mice. by Ghulam Murtaza (2559319)

Distinct effects on calcium channel activation of <i>CACNA1I</i> disease-associated amino acid substitutions A398E/V and M1425V/I. by Yousra El Ghaleb (22075892)

Deletion of <i>NUO2</i> triggers a ROS-dependent signaling pathway involving Hog1 activation and Brg1 repression in conditions when mannitol is the sole carbon source. by Xinhua Huang (1905940)

Data Sheet 2_Reducing ocular Demodex using petroleum jelly may alleviate dry eye syndrome, blepharitis, facial dermatoses, ocular and respiratory allergies, and decrease associated... by Diana E. Senior-Fletcher (22090340)

“…Mean yearly issues of anti-allergy and antimicrobial medicines reduced from 15.6 (range 8–25) to 1.8 (range 0–4), representing an 88.5% decrease for Volunteer 1 and from 5.8 (range 3–9) and 14.2 issues (range 9–24) to zero for both Volunteer 2 and Volunteer 13 respectively, representing 100% reductions in prescribing. …”

Data Sheet 1_Reducing ocular Demodex using petroleum jelly may alleviate dry eye syndrome, blepharitis, facial dermatoses, ocular and respiratory allergies, and decrease associated... by Diana E. Senior-Fletcher (22090340)

“…Mean yearly issues of anti-allergy and antimicrobial medicines reduced from 15.6 (range 8–25) to 1.8 (range 0–4), representing an 88.5% decrease for Volunteer 1 and from 5.8 (range 3–9) and 14.2 issues (range 9–24) to zero for both Volunteer 2 and Volunteer 13 respectively, representing 100% reductions in prescribing. …”

Bee Venom for the Treatment of Parkinson Disease – A Randomized Controlled Clinical Trial by Andreas Hartmann (241073)

“…We conducted a prospective, randomized double-blind study in 40 Parkinson disease patients at Hoehn & Yahr stages 1.5 to 3 who were either assigned to monthly bee venom injections or equivalent volumes of saline (treatment/placebo group: n = 20/20). …”